Comparative Pharmacology
Head-to-head clinical analysis: PROMETHAZINE DM versus TEMARIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PROMETHAZINE DM versus TEMARIL.
PROMETHAZINE DM vs TEMARIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Promethazine is a phenothiazine derivative that acts as a histamine H1 receptor antagonist, antiemetic via blockade of dopamine D2 receptors in the chemoreceptor trigger zone, and sedative via central anticholinergic effects. Dextromethorphan is an NMDA receptor antagonist and sigma-1 receptor agonist, suppressing cough by central action on the cough center.
Temaril (trimeprazine tartrate and prednisolone) combines an antipruritic phenothiazine antihistamine with a corticosteroid. Trimeprazine blocks histamine H1 receptors, reducing pruritus and allergic reactions. Prednisolone suppresses inflammation via glucocorticoid receptor activation, inhibiting phospholipase A2 and cytokine production.
2 teaspoonfuls (10 mL) orally every 4-6 hours, not to exceed 8 teaspoonfuls (40 mL) per 24 hours.
2.5 mg orally twice daily or 5 mg orally at bedtime; maximum 10 mg/day.
None Documented
None Documented
16-19 hours (terminal); note: effect may last longer due to active metabolites and tissue binding
Terminal elimination half-life is 9–12 hours in adults; prolonged in hepatic impairment (up to 20 hours). Given TID dosing, steady state is reached within 2 days.
Renal (70-80% as metabolites, <1% unchanged); biliary/fecal (20-30%)
Primarily via kidneys as metabolites; unchanged drug accounts for <1%. Biliary/fecal excretion is minor. Approx. 90% recovered in urine within 24 hours.
Category A/B
Category C
Antihistamine / Antiemetic
Antihistamine